Tacrine (9-amino-1,2,3,4-tetrahydroacridine) 11 is a potent inhibitor of AChE and is the first approved drug by the FDA in 1993 for the treatment of AD [66]. Although due to adverse side …

2012年4月7日 · Tacrine is about 55% bound to plasma proteins and has a clinical half-life of 3–6 h following a single oral dose. Major metabolism of tacrine takes place in the liver via …

Tacrine, the first drug approved in 1993 for AD, is a potent centrally acting reversible cholinesterase inhibitor. Oral administration of tacrine shows problems such as extensive first …

2017年4月3日 · Tacrine was also shown to protect cultures of rat cortical neurons against glutamate-induced neurotoxicity involving apoptotic neuronal death. Tacrine protected cells …

1991年1月1日 · https://doi.org/10.1016/0301-0082(91)90002-I Get rights and content

Tacrine is a white crystalline water-soluble powder that has been found to have various pharmacological actions, including the ability to antagonize respiratory depression and …

Tacrine was the first AChEI to get approval by the Food and Drug Administration (FDA) agency in 1993 to treat mild to moderate symptoms associated with AD. Despite the somewhat …

1991年4月27日 · The Lancet ORIGINAL ARTICLES Tacrine in Alzheimer's disease S.A. Eagger MRCPsych Prof R. Levy FRCPsych * * Correspondence to Prof Raymond Levy. B.J. Sahakian …

In this study, novel multi-target tacrine-trolox and tacrine-tryptoline hybrids were designed, synthesized and evaluated for ChE inhibition and free radical scavenging activity. All the …

2021年7月5日 · In summary, we hypothesize that the clinical efficacy of tacrine is also co-determined by the NMDAR-antagonizing activity. Thus, compounds structurally related to …